On Wednesday, Shares of JD.com, Inc. (NASDAQ:JD), lost -4.45% to $26.77, as U.S. traded China-based stocks continue to get slammed after the Chinese central bank devalued the yuan.
China devalued its currency for a second successive day with the yuan falling as much as 1.98% on Wednesday, following Tuesday’s decision to weaken the currency by close to 2%, The Wall Street Journal reports.
JD.com, Inc., through its auxiliaries, operates as an online direct sales company in the People’s Republic of China. It primarily offers electronics and home appliances products; and general merchandise products, counting audio and video products, and books.
Shares of Noble Corporation plc (NYSE:NE), inclined 3.89% to $13.61, during its last trading session, as Oil closed higher on Wednesday as a weaker dollar and lower U.S. crude stockpiles offered a modest bounce off six-year lows hit the previous session, when worries about China’s plummeting currency and economic slowdown sank prices, according to CNBC.
U.S. light crude oil settled up 22 cents, or 0.5 percent, at $43.30 a barrel, after gaining almost 80 cents at the session high. On Tuesday, the market fell $1.88, or more than 4 percent, to settle at $43.08 a barrel, its lowest close since March 2009.
Benchmark Brent crude oil was up 53 cents a barrel at $49.70, after a session high at $49.91. CNBC Reports
Noble Corporation plc operates as an offshore drilling contractor for the oil and gas industry worldwide. It owns and operates a fleet of mobile offshore drilling units. As of December 31, 2014, the company operated a fleet of 15 jackups, 9 drillships, and 8 semisubmersibles, counting 1 high-specification, harsh environment jackup under construction.
Finally, Exelixis, Inc. (NASDAQ:EXEL), ended its last trade with 2.27% gain, and closed at $5.85.
Exelixis stated financial results for the second quarter of 2015 and offered an update on progress toward delivering upon its key 2015 corporate objectives and clinical development milestones.
METEOR Trial Delivers Positive Top-Line Results in Advanced RCC. In July 2015, Exelixis declared that METEOR met its primary endpoint, demonstrating a statistically noteworthyimprovement in progression-free survival (PFS) for cabozantinib as compared to everolimus in a population of patients with advanced renal cell carcinoma who have practiced disease progression following treatment with at least one preceding VEGFR tyrosine kinase inhibitor. The primary analysis was conducted on the first 375 patients enrolled, and the hazard ratio (HR) was 0.58 (95% CI 0.45-0.75, p<0.0001), equating to a 42% decrease in the risk of disease progression or death for the cabozantinib arm. As predictable, data pertaining to overall survival (OS) for the entire 658-patient study population were not mature at the data cut-off, but a pre-planned interim analysis showed a trend favoring cabozantinib (HR=0.67, unadjusted 95 percent CI 0.51-0.89; p=0.005). At the time of the interim analysis, the pre-specified p-value of 0.0019 to achieve statistical significance was not reached. The trial will continue to the final OS analysis anticipated in 2016. The frequency of serious adverse events of any grade, regardless of causality, was about balanced between study arms, and the rate of discontinuations for adverse events was low (10%) in both arms.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
